victrellis

[Linda5758]

I am on victrellis, is there a difference on the outcome of using vic verses icevek?  people seem to have a lot of problems with the incevik, victrellis dosn't really seem to bother me much, just the peginferon knocks me down for about 3 or 4 days.

[Linda5758]

thanks you all for your very important info, I don't know what I'd do without you!!! Thank-you so much.

[BoceprevirGal]

  Hi, Linda: the Victrelis pills never rly bothered me either, surprisingly, since I usually am the type ofperson that hates to even take a course of antibiotics!
    The reaction you are describing, from your Interferon shot, also usually eases up, by 12 weeks, as our bodies get used to the drug, and we have a steady level in our bodies, so we no longer react as strongly usually. Although, dont expect the usual, because even at the end of my 28 week Treatment, rogue side effects would crop up, out of nowhere.
    The Ribaviran pills tend to be the lil culprits, that run our hemoglobin down, giving us "hemolytic anemia", but this doesn't happen to everybody either~  My anemia set in, around 7 weeks, so keep an eye on your labs, where it says "hemoglobin".  There is a "rescue drug" called Procrit, which sometimes helps with this, but it's best to start in early, on it, if your hgb drops below 10~
  

[hrsepwrguy]

"is there a difference on the outcome of using vic verses icevek?"

No, they are both good drugs with about the same SVR rate

Boceprevir and telaprevir are the first two protease inhibitors available for the treatment of patients infected with hepatitis C virus (HCV) genotype 1. A sustained virological response (SVR) of 70–80% is observed when either of these protease inhibitors is utilized with pegylated interferon (PEG-IFN) and ribavirin (RBV) in treatment naïve patients. Both agents are also highly effective in patients who failed to achieve a SVR during previous treatment with PEG-IFN/RBV. A rapid virological response (RVR) is observed in 56–60% of treatment naïve patients. Patients who achieve a RVR can be treated with a shorter course of therapy (24–28 weeks) and still achieve a SVR rate of 90% or higher. Patients who do not achieve a RVR, those with cirrhosis and certain prior non-responders should be treated for 48 weeks. Although the SVR rates observed with boceprevir and telaprevir are quite similar both globally and within sub-populations, the treatment algorithms for the two agents are unique. The decision of which protease inhibitor to use should assess several factors including the treatment scheme, duration of therapy, adverse event profile, cost and the likelihood of achieving a RVR. The latter is highly dependent upon IFN sensitivity and the IL28B genotype.

http://onlinelibrary.wiley.com/doi/10.1111/j.1478-3231.2011.02718.x/full

[willbb]

In trials for both these therapies.the overall SVR outcome was relatively similar

There are obviously different dosage regimes ,total time frames .and somewhat differing side effects.

The article below by the famed Hepatolgogist DR. Shiffman might help to explain all the rates of success for both these drugs and their differences.

Good luck with your tx..


http://onlinelibrary.wiley.com/doi/10.1111/j.1478-3231.2011.02718.x/full

Will